Novartis' Zelnorm is back, but only through a restricted-access program.
Severin Schwan takes over at Roche
Spending expected to increase mildly in the short term
In the wake of a high-profile death from counterfeit drugs, the industry reacts
How a $65,000 dinner tab led to new reporting rules for Australian pharma
...And the spurned suitor won't take "No" for an answer
But is the pharma-biotech vaccine deal a prelude to a takeover?
Blockbuster antidepressants linked to bone loss in seniors
Catching up with the first ouchless fast test on National HIV Testing Day
How Digital Medicine Can Pinpoint Dosing Regimens to Optimize Drug Efficacy and Safety
Sponsored By Oracle
Multi-faceted Approaches to Meet Payer and Regulatory Evidence Requirements
Sponsored By UBC Express Scripts
Overcoming the Life Sciences Content Conundrum in a Multichannel World
Sponsored By Veeva